{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-21-309692","form_type":"8-K","ticker":"LYEL","cik":"0001806952","company_name":"Lyell Immunopharma, Inc.","filed_at":"2021-10-28T23:59:59+00:00","discovered_at":"2026-05-14T18:04:14.228061+00:00","generated_at":"2026-06-28T16:55:57.156451+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Lyell Immunopharma promotes Stephen Hill to COO effective Nov 1, 2021","bullets":["Stephen Hill promoted from Chief Technical Operations Officer to Chief Operating Officer, effective November 1, 2021.","Hill joined Lyell in June 2019; prior roles include SVP at AstraZeneca and VP at Amgen.","New base salary of $485,000 with an annual bonus target of up to 55% of base salary.","No family relationships with directors or executive officers; no arrangements with other persons.","Employment is at-will; successor not appointed; no departure of any other officer."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-21-309692","json":"https://secwatch.observer/filing/0001193125-21-309692.json","markdown":"https://secwatch.observer/filing/0001193125-21-309692.md","text":"https://secwatch.observer/filing/0001193125-21-309692.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1806952/000119312521309692/0001193125-21-309692-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1806952/000119312521309692/d250716d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T16:55:57.156451+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"fc4baeba29","claim":"Stephen Hill changed role as Chief Operating Officer at Lyell Immunopharma, Inc..","evidence_excerpt":"On October 23, 2021, the compensation committee (the “Compensation Committee) of the board of directors (the “Board”) of Lyell Immunopharma, Inc. (the “Company”) approved the promotion of Stephen Hill, the Company’s Chief Technical Operations Officer, to the position of Chief Operating Officer, to serve in such position until his successor is appointed or until his earlier resignation or removal. Such promotion will be effective on November 1, 2021.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1806952/000119312521309692/0001193125-21-309692-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"promoted"},{"label":"Role","value":"Chief Operating Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}